FR2951172B1 - Derives pyrazolopyridines en tant qu'agent anticancereux - Google Patents

Derives pyrazolopyridines en tant qu'agent anticancereux

Info

Publication number
FR2951172B1
FR2951172B1 FR0957140A FR0957140A FR2951172B1 FR 2951172 B1 FR2951172 B1 FR 2951172B1 FR 0957140 A FR0957140 A FR 0957140A FR 0957140 A FR0957140 A FR 0957140A FR 2951172 B1 FR2951172 B1 FR 2951172B1
Authority
FR
France
Prior art keywords
cancer agent
pyrazolopyridine derivatives
pyrazolopyridine
derivatives
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0957140A
Other languages
English (en)
French (fr)
Other versions
FR2951172A1 (fr
Inventor
Karim Bedjeguelal
Remi Rabot
El Bachir Kaloun
Patrice Mayer
Arnaud Marchand
Nicolas Rahier
Philippe Schambel
Hugues Bienayme
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR0957140A priority Critical patent/FR2951172B1/fr
Priority to PCT/EP2010/065346 priority patent/WO2011045344A1/en
Priority to US13/500,757 priority patent/US8889711B2/en
Priority to EP10770774.7A priority patent/EP2488519B1/en
Priority to JP2012533621A priority patent/JP5833010B2/ja
Publication of FR2951172A1 publication Critical patent/FR2951172A1/fr
Application granted granted Critical
Publication of FR2951172B1 publication Critical patent/FR2951172B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0957140A 2009-10-13 2009-10-13 Derives pyrazolopyridines en tant qu'agent anticancereux Expired - Fee Related FR2951172B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0957140A FR2951172B1 (fr) 2009-10-13 2009-10-13 Derives pyrazolopyridines en tant qu'agent anticancereux
PCT/EP2010/065346 WO2011045344A1 (en) 2009-10-13 2010-10-13 Pyrazolopyridine derivatives as anticancer agent
US13/500,757 US8889711B2 (en) 2009-10-13 2010-10-13 Pyrazolopyridine derivatives as anticancer agent
EP10770774.7A EP2488519B1 (en) 2009-10-13 2010-10-13 Pyrazolopyridine derivatives as anticancer agent
JP2012533621A JP5833010B2 (ja) 2009-10-13 2010-10-13 抗癌剤としてのピラゾロピリジン誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0957140A FR2951172B1 (fr) 2009-10-13 2009-10-13 Derives pyrazolopyridines en tant qu'agent anticancereux

Publications (2)

Publication Number Publication Date
FR2951172A1 FR2951172A1 (fr) 2011-04-15
FR2951172B1 true FR2951172B1 (fr) 2014-09-26

Family

ID=42112290

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0957140A Expired - Fee Related FR2951172B1 (fr) 2009-10-13 2009-10-13 Derives pyrazolopyridines en tant qu'agent anticancereux

Country Status (5)

Country Link
US (1) US8889711B2 (enExample)
EP (1) EP2488519B1 (enExample)
JP (1) JP5833010B2 (enExample)
FR (1) FR2951172B1 (enExample)
WO (1) WO2011045344A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
DE102011105469A1 (de) * 2011-06-24 2012-12-27 Merck Patent Gmbh 7-Azaindolderivate
EP2760862B1 (en) * 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
US10138235B2 (en) 2011-12-14 2018-11-27 Sanofi Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
FR2985257B1 (fr) * 2011-12-28 2014-02-14 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
CN103214470A (zh) * 2012-01-18 2013-07-24 杨更亮 酮类与吲哚衍生物反应合成的新型抗癌化合物
EP2847191B1 (en) 2012-05-09 2016-06-15 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
ES2563861T3 (es) 2012-06-14 2016-03-16 Daiichi Sankyo Company, Limited Derivado de piperidinilpirazolopiridina
EA025186B1 (ru) 2012-06-29 2016-11-30 Пфайзер Инк. НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) * 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016115272A1 (en) 2015-01-13 2016-07-21 Vanderbilt University Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016205460A1 (en) * 2015-06-16 2016-12-22 Nantbioscience, Inc. Polycyclic derivatives targeting ral gtpases and their therapeutical applications
CA2992586A1 (en) * 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
AU2017294231B2 (en) * 2016-07-05 2021-09-09 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
AR111473A1 (es) * 2017-04-19 2019-07-17 Sumitomo Chemical Co Método para la preparación de compuesto de piridina
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN111032646B (zh) 2017-08-01 2023-01-03 施万生物制药研发Ip有限责任公司 作为jak激酶抑制剂的吡唑并和三唑并双环化合物
KR102666727B1 (ko) 2017-12-29 2024-05-21 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. 방향족 비닐 또는 방향족 에틸계 유도체, 그의 제조방법, 중간체, 약물조성물 및 용도
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202246259A (zh) * 2021-01-29 2022-12-01 瑞士商赫孚孟拉羅股份公司 吡唑醯胺衍生物
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
CN119968359A (zh) 2022-09-29 2025-05-09 英矽智能科技知识产权有限公司 Tead抑制剂及其使用方法
WO2025190406A1 (en) * 2024-03-15 2025-09-18 Insilico Medicine Ip Limited Tead inhibitor combinations and uses thereof
WO2025209524A1 (en) * 2024-04-03 2025-10-09 Insilico Medicine Ip Limited Crystalline tead inhibitor and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227932B1 (en) * 1985-12-13 1993-01-13 American Cyanamid Company Novel fused pyridine compounds, intermediates for the preparation of, and use of said compounds as herbicidal agents
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
EP1537106A1 (en) 2002-08-07 2005-06-08 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
US20040142978A1 (en) * 2002-12-12 2004-07-22 Pharmacia Corporation Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
UA81453C2 (en) * 2003-02-27 2008-01-10 Pyrazolopyridine derivates
US7872014B2 (en) * 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
ATE415400T1 (de) * 2004-07-05 2008-12-15 Astellas Pharma Inc Pyrazolopyridinderivate
KR101011958B1 (ko) * 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 ｐ38 ＭＡＰ 키나아제 저해제로서의 융합형 피라졸
WO2009006580A1 (en) * 2007-07-05 2009-01-08 Cv Therapeutics, Inc. Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer

Also Published As

Publication number Publication date
US20120245170A1 (en) 2012-09-27
JP5833010B2 (ja) 2015-12-16
JP2013507425A (ja) 2013-03-04
FR2951172A1 (fr) 2011-04-15
WO2011045344A1 (en) 2011-04-21
EP2488519A1 (en) 2012-08-22
EP2488519B1 (en) 2015-06-10
US8889711B2 (en) 2014-11-18

Similar Documents

Publication Publication Date Title
FR23C1039I2 (fr) Derives de piperidinone carboxamide azaindane en tant qu'antagonistes du recepteur cgrp
EP2890691A4 (en) BENZIMIDAZOLE DERIVATIVES AS ICT INHIBITORS
BRPI1009118A2 (pt) 3h-imidazo[4,5-c] piridina-6-carboxamidas como agentes anti-inflamatórios
EP2320737A4 (en) PYRAZOLO- [1,5-A] -PYRIDINE AS MARK HEMMER
BRPI0919292A2 (pt) 3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios
SMT201500316B (it) Derivati di benzotiazolo come agenti anticancro
AP3862A (en) Novel benzimidazole derivatives as ep4 antagonists
FR3000492B1 (fr) Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
EP2654748A4 (en) INDAZONE DERIVATIVES AS ERK HEMMER
EP2863914A4 (en) PYRAZOLYL DERIVATIVES AS SYK-HEMMER
EP2667874A4 (en) MTOR KINASE HEMMER AS ANTIVIRUS AGENT
EP2888007A4 (en) NOVEL BENZIMIDAZOLTETRAHYDROFURANDERIVATE
DK2401270T3 (da) Pyrazolderivater anvendt som CCR4-receptorantagonister.
EP2685992A4 (en) AMINOCHINOLINE AS A KINASEHEMMER
IT1393337B1 (it) Sintesi di (4as, 7as)-ottaidro-1h-pirrolo[3,4-b]piridina
EP2346866A4 (en) BETA-CARBOLINE-SULPHONYL HARVESIDE DERIVATIVES AS EP4-RECEPTOR ANTAGONISTS
ZA201403195B (en) Pharmaceutical compositions of hydrophobic camptothecin derivatives
HUE042978T2 (hu) Antibakteriális ciklopenta[c]pirrol-szubsztituált 3,4-dihidro-1H-[1,8]naftiridon-származékok
IL207972A0 (en) Pyridin-2-yl derivatives as immunomodulating agents
BR112013013837A2 (pt) derivados de substituição de imidazoquinolina
EP2922543A4 (en) SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS
EP2685824A4 (en) INDUSTRIAL DERIVATIVES USED AS CCR2 ANTAGONISTS
EP2714041A4 (en) ARYLOXYMETHYL-CYCLOPROPAN DERIVATIVES AS PDE10 INHIBITORS
EP2461805A4 (en) SPECTINAMID AS A MEDIUM AGAINST TUBERCULOSIS
ZA201306643B (en) Formulation comprising phenylaminopyrimidine derivatives as active agent

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

ST Notification of lapse

Effective date: 20180629